Nanjing Xinjiekou Department Store Co., Ltd. (SHSE:600682) agreed to acquire 76% stake in Shandong Qilu Stem Cells Engineering Co., Ltd. from Xinyu Chuangli Hengyuan Investment Management Co., Ltd., Yinfeng Biological Group, Ltd, Wang Wei, Wang Shan and Shen Baijun for CNY 3.4 billion on January 9, 2016. Under the terms of the transaction, Nanjing Xinjiekou Department will issue approximately 180 million shares at CNY 18.6 per share. Wang Wei will sell 4% stake and Wang Shan and Shen Baijun will sell 1% stake, each. In related transactions, Nanjing Xinjiekou Department Store Co., Ltd agreed to acquire Sanpower International Healthcare Group Limited 100% stake and Nanjing Xinjiekou Department Store Co., Ltd agreed to acquire 84% stake in Home & Health Care Holding Limited. At the same time, Nanjing Xinjiekou Department Store will issue shares to not more than 10 specific investors to raise supporting funds of CNY 350 million.

As of December 31, 2015, Shandong Qilu Stem Cells Engineering had total assets of CNY 963.87 million, owner's equity of CNY 249.83 million, revenue of CNY 359.45 million, operating profit of CNY 186.04 million and net profit of CNY 159.01 million. The transaction is subject to approval of shareholders of Nanjing Xinjiekou Department Store and CSRC. The transaction has been approved by Board of Directors of Nanjing Xinjiekou Department Store on January 8, 2016. In January 2016, Shandong Qilu Stem Cells Engineering's shareholders' meeting approved the transaction. As on August 31, 2016, the shareholders of Nanjing Xinjiekou Department Store Co approved the deal. On January 13, 2017, the transaction was approved by China Securities Regulatory Commission. Huatai United Securities Co., Ltd. acted as financial advisor, Zhong Lun Law Firm acted as legal advisor and Suya Jincheng Certified Public Accountants acted as accountant for Nanjing Xinjiekou Department Store.